Ranbaxy Laboratories slumped 23.85% to Rs 348.20 at 9:53 IST on BSE after the US Food and Drug Administration issued an import alert against company's Mohali plant in Punjab on Friday, 13 September 2013.
Meanwhile, the BSE Sensex was up 242.34 points, or 1.23%, to 19,975.10.
On BSE, 22.77 lakh shares were traded in the counter compared with average volume of 5.60 lakh shares in the past one quarter.
The stock hit a high of Rs 411.55 and a low of Rs 297.25 so far during the day. The stock hit a 52-week high of Rs 559.95 on 14 September 2012. The stock hit a 52-week low of Rs 253.95 on 2 August 2013.
The stock had outperformed the market over the past one month till 13 September 2013, rising 14.83% compared with the Sensex's 2.62% rise. The scrip had also outperformed the market in past one quarter, gaining 22.31% as against Sensex's 4.81% rise.
The large-cap company has an equity capital of Rs 211.56 crore. Face value per share is Rs 5.
Ranbaxy Laboratories' plant in Mohali manufactures oral solids for export to the US, the European Union and other geographies.
In May 2013, Ranbaxy Laboratories agreed to pay $500 million penalty to the US government to settle criminal and civil charges related to drug safety.
Ranbaxy Laboratories reported consolidated net loss of Rs 524.24 crore in Q2 June 2013, lower than net loss of Rs 585.72 crore in Q2 June 2012. Net sales declined 17.8% to Rs 2633.20 crore in Q2 June 2013 over Q2 June 2012.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of generic medicines. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group.
Powered by Capital Market - Live News
